FDA approves VIZZ eye drops: A new option for presbyopia
HQ Team August 11, 2025: The US Food and Drug Administration (FDA) has granted approval to VIZZ (aceclidine ophthalmic solution 1.44%), an innovative.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team August 11, 2025: The US Food and Drug Administration (FDA) has granted approval to VIZZ (aceclidine ophthalmic solution 1.44%), an innovative.
HQ Team August. 11, 2025: Novartis AG announced positive Phase III trial results for its experimental autoimmune drug, Ianalumab (VAY736), in treating Sjögren’s.
About 67 million people globally living with chronic fatigue syndrome have different genes compared to their healthy counterparts, initial findings from the world's.
Jazz Pharmaceuticals Plc’s treatment for a rare and aggressive brain tumour that affects children and adults got approval from the US regulator.
Hanuman complex is very much implied in positive psychology in this sense. It helps individuals to rediscover their hidden potential. Rooted in Hanuman’s.
The Gates Foundation will support more than 40 innovations in five chronically underfunded areas in women’s health by spending $2.5 billion over the.
A 15-minute fast walk helped reduce mortality by 20%, mostly in low-income Black individuals in the US, a study finds.
HQ Team August 2, 2025: A new study conducted by Moritz Reis from the University of Wuerzburg in Germany and colleagues has shed.
HQ Team August 2, 2025: A study published in JAMA Oncology is challenging the conventional belief that men diagnosed with Grade Group One.
HQ Team July 30, 2025: The US Food and Drug Administration has approved Apellis Pharmaceuticals, Inc.’s medicine for treating two rare and serious.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com